F
1.92
0.02 (1.05%)
| Previous Close | 1.90 |
| Open | 1.91 |
| Volume | 131,833 |
| Avg. Volume (3M) | 319,617 |
| Market Cap | 92,349,888 |
| Price / Sales | 1.02 |
| Price / Book | 1.97 |
| 52 Weeks Range |
| Operating Margin (TTM) | -169,957.14% |
| Diluted EPS (TTM) | -1.58 |
| Quarterly Revenue Growth (YOY) | -61.10% |
| Total Debt/Equity (MRQ) | 125.06% |
| Current Ratio (MRQ) | 5.58 |
| Operating Cash Flow (TTM) | -59.09 M |
| Levered Free Cash Flow (TTM) | -36.66 M |
| Return on Assets (TTM) | -55.32% |
| Return on Equity (TTM) | -286.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Fractyl Health, Inc. | Mixed | - |
AIStockmoo Score
0.7
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.0 |
| Average | 0.67 |
|
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 4.84% |
| % Held by Institutions | 86.04% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Deer Management Co. Llc | 30 Sep 2024 | 4,770,901 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |